Why is this study being conducted?

Early Alzheimer’s disease (AD) refers to two situations that are often caused by the presence of AD in the brain. The first is mild cognitive impairment, which means that there are some changes in memory or thinking but that these are not interfering with a person’s daily life or independence. The second is mild dementia due to AD, which means that the changes in memory are more noticeable, and a person may require help with some areas of daily life.

We are doing this study to investigate if a new study medication can reduce the loss of memory and decline in daily functioning usually seen in early AD.

Who is eligible to participate in this study?

You may be able to take part in the Early AD Trial if you:

  • Are between 50 and 85 years of age
  • Have early Alzheimer’s disease
  • Weigh between 45 kg and 120 kg, with a BMI between 17 and 34.9 kg/m2

Additional eligibility criteria may apply and will be discussed directly with the Clinical Trial Coordinator.

What happens during the study?

  • Trial duration will be up to 100 weeks (approx 2 years) and participants will have about 25 trial visits.
  • Trial visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
  • Participants will attend MRI and PET scans throughout the trial.
  • Participants are required to have a study partner to attend visits with them.

Participation in this study is completely voluntary, and participants can decide to withdraw at any time.

Eligible participants will be reimbursed for their travel associated with each study visit.

For further information please contact Anna Fahd (Clinical Trial Coordinator) on 5672 7260 or email: [email protected].

Ethics approval number for the Early AD Trial: Bellberry Limited 2023-07-895-AA, GU HREC 2023/876